 |
A
call for sponsorship to support the running and future development
of Glycosmedia |
| |
Click on the above headline for an overview
of the Glycosmedia diabetes news service and our call for sponsorship.
Brief details on how sponsorship will work can be seen here. For further details please contact (Jim Young, Editor-in-Chief) |
| |
|
|
Prevention
of diabetes and cardiovascular disease in patients with impaired
glucose tolerance |
| |
Rationale and design of the Nateglinide And
Valsartan in Impaired Glucose Tolerance Outcomes Research Trial
(PubMed) |
| |
|
|
Canadian
Diabetes Association Awards |
| |
A list of the 5 awards announced on 24th October
(Canadian Diabetes Association) |
| |
|
|
The
European Medicines Agency recommends suspension of the marketing
authorisation of Acomplia |
| |
Acomplia has been authorised in the EU since
June 2006 as an adjunct to diet and exercise for the treatment
of obese patients or overweight patients with associated risk factors
(EMEA) |
| |
|
|
Sanofi's
Acomplia looks doomed after EU suspension |
| |
The CHMP said the new data from “post-marketing
experience and ongoing clinical trials indicated that serious psychiatric
disorders may be more common than in the clinical trials used in
the initial assessment of the medicine”. (PharmaTimes) |
| |
|
|
Sources
of funding |
| |
If you know of any sources of funding that we
can contact to support the running and future development of Glycosmedia
then please mail Jim Young, Editor-in-Chief jim@glycosmedia.com |
| |
|
